Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
Rong Xiang,Yang Wang,Lili Wang,Xiaoqian Deng,Shanshan Huo,Shibo Jiang,Fei Yu
DOI: https://doi.org/10.1016/j.coviro.2021.12.015
IF: 7.121
2022-04-01
Current Opinion in Virology
Abstract:The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.
virology
What problem does this paper attempt to address?